High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer

Background and objectives We explored the prognostic usefulness of the pan-immune-inflammation value (PIV) in patients with stage IIIB/C non-small-cell lung cancer (NSCLC) who underwent concurrent chemoradiotherapy (CCRT). Methods and patients For all patients, the PIV was calculated using platelet...

Full description

Saved in:
Bibliographic Details
Published in:Discover. Oncology 2023-12, Vol.14 (1), p.230-230, Article 230
Main Authors: Topkan, Erkan, Kucuk, Ahmet, Ozkan, Emine Elif, Ozturk, Duriye, Besen, Ali Ayberk, Mertsoylu, Huseyin, Pehlivan, Berrin, Selek, Ugur
Format: Article
Language:English
Subjects:
Biochemistry
Biological marker
Biomarkers
Blood tests
Cancer Research
Cancer therapies
Chemotherapy
Clinical medicine
Histology
Immunotherapy
Inflammation
Internal Medicine
Lung cancer
Lung diseases
Lymphatic system
Medicine
Medicine & Public Health
Metastasis
Molecular Medicine
Neutrophils
Non-small-cell lung cancer
Oncology
Pan-immune-inflammation value
Patients
Prognosis survival
Radiotherapy
Surgical Oncology
Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and objectives We explored the prognostic usefulness of the pan-immune-inflammation value (PIV) in patients with stage IIIB/C non-small-cell lung cancer (NSCLC) who underwent concurrent chemoradiotherapy (CCRT). Methods and patients For all patients, the PIV was calculated using platelet (P), monocyte (M), neutrophil (N), and lymphocyte (L) measures obtained on the first day of CCRT: PIV = P × M × N ÷ L. Using receiver operating characteristic (ROC) curve analysis, we searched for the existence of an ideal cutoff that may partition patients into two groups with unique progression-free- (PFS) and overall survival (OS) results. The primary endpoint of this retrospective cohort research was to determine whether there were any significant relationships between pretreatment PIV measures and post-CCRT OS outcomes. Results The present research included a total of 807 stage IIIB/C NSCLC patients. According to ROC curve analysis, the ideal PIV cutoff was 516 [area under the curve (AUC): 67.7%; sensitivity: 66.4%; specificity: 66.1%], which divided the whole cohort into two: low PIV (L-PIV: PIV 
ISSN:2730-6011
2730-6011
DOI:10.1007/s12672-023-00851-8